Cilostazol for intermittent claudication

Real world data from a multi-centre study on the effects of cilostazol on pain symptoms and walking distance in patients with peripheral arterial disease

“…In the present study among 1015 PAD patients with IC, cilostazol significantly increased pain-free walking distance by 285 m at 3 months and 387 m at 6 months, irrespective of lifestyle changes and comorbidities. This finding is in agreement with previous evidence from Cochrane reviews [ 12 – 14 ] and guidelines [ 10 ]. The benefit was also observed, but lost its significance, in the older PAD patients (i.e., aged ≥ 75 years).…”

“…No treatment discontinuation was reported. This agrees with its overall safety profile [12][13][14] and guidelines [11].…”

Real world data from a multi-centre study on the effects of cilostazol on pain symptoms and walking distance in patients with peripheral arterial disease

“…In the present study among 1015 PAD patients with IC, cilostazol significantly increased pain-free walking distance by 285 m at 3 months and 387 m at 6 months, irrespective of lifestyle changes and comorbidities. This finding is in agreement with previous evidence from Cochrane reviews [ 12 – 14 ] and guidelines [ 10 ]. The benefit was also observed, but lost its significance, in the older PAD patients (i.e., aged ≥ 75 years).…”

“…No treatment discontinuation was reported. This agrees with its overall safety profile [12][13][14] and guidelines [11].…”

Efficacy and Safety of Fixed-Dose Combination Therapy With Cilostazol and Rosuvastatin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease: A Multicenter Randomized Controlled Trial

“…1), suggesting that patient-reported improvement was accompanied by objective functional gain among treatment responders. These findings are consistent with previous data demonstrating improvements in claudication symptoms and walking performance with cilostazol therapy [10,11,20] and support the value of disease-specific patient-reported outcomes for evaluating clinically significant treatment benefits in PAD [16,17].…”

“…The fixed-dose combination of cilostazol and rosuvastatin was generally well-tolerated, with adverse events consistent with established safety profile of cilostazol. The higher incidence of diarrhea, headache, and palpitations in the combination therapy group was comparable to previous reports and rarely resulted in treatment discontinuation [9,20,25]. No unexpected safety signals were identified, and no serious adverse events were considered related to study medication.…”

One-year follow-up of patients screened for lower extremity arterial disease

“…This positive change could be attributed to the increased walking distance achieved through medication therapies. According to our expectations, the greatest improvements were measured with patients taking cilostazol-containing medications, which is consistent with the results of other previous studies in the literature [26,[56][57][58][59].…”

Real world data from a multi-centre study on the effects of cilostazol on pain symptoms and walking distance in patients with peripheral arterial disease

“…In the present study among 1015 PAD patients with IC, cilostazol significantly increased pain-free walking distance by 285 m at 3 months and 387 m at 6 months, irrespective of lifestyle changes and comorbidities. This finding is in agreement with previous evidence from Cochrane reviews [ 12 – 14 ] and guidelines [ 10 ]. The benefit was also observed, but lost its significance, in the older PAD patients (i.e., aged ≥ 75 years).…”

“…No treatment discontinuation was reported. This agrees with its overall safety profile [12][13][14] and guidelines [11].…”

Efficacy and Safety of Fixed-Dose Combination Therapy With Cilostazol and Rosuvastatin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease: A Multicenter Randomized Controlled Trial

“…1), suggesting that patient-reported improvement was accompanied by objective functional gain among treatment responders. These findings are consistent with previous data demonstrating improvements in claudication symptoms and walking performance with cilostazol therapy [10,11,20] and support the value of disease-specific patient-reported outcomes for evaluating clinically significant treatment benefits in PAD [16,17].…”

“…The fixed-dose combination of cilostazol and rosuvastatin was generally well-tolerated, with adverse events consistent with established safety profile of cilostazol. The higher incidence of diarrhea, headache, and palpitations in the combination therapy group was comparable to previous reports and rarely resulted in treatment discontinuation [9,20,25]. No unexpected safety signals were identified, and no serious adverse events were considered related to study medication.…”

One-year follow-up of patients screened for lower extremity arterial disease

“…This positive change could be attributed to the increased walking distance achieved through medication therapies. According to our expectations, the greatest improvements were measured with patients taking cilostazol-containing medications, which is consistent with the results of other previous studies in the literature [26,[56][57][58][59].…”

Real world data from a multi-centre study on the effects of cilostazol on pain symptoms and walking distance in patients with peripheral arterial disease

“…In the present study among 1015 PAD patients with IC, cilostazol significantly increased pain-free walking distance by 285 m at 3 months and 387 m at 6 months, irrespective of lifestyle changes and comorbidities. This finding is in agreement with previous evidence from Cochrane reviews [ 12 – 14 ] and guidelines [ 10 ]. The benefit was also observed, but lost its significance, in the older PAD patients (i.e., aged ≥ 75 years).…”

“…No treatment discontinuation was reported. This agrees with its overall safety profile [12][13][14] and guidelines [11].…”

Efficacy and Safety of Fixed-Dose Combination Therapy With Cilostazol and Rosuvastatin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease: A Multicenter Randomized Controlled Trial

“…1), suggesting that patient-reported improvement was accompanied by objective functional gain among treatment responders. These findings are consistent with previous data demonstrating improvements in claudication symptoms and walking performance with cilostazol therapy [10,11,20] and support the value of disease-specific patient-reported outcomes for evaluating clinically significant treatment benefits in PAD [16,17].…”

“…The fixed-dose combination of cilostazol and rosuvastatin was generally well-tolerated, with adverse events consistent with established safety profile of cilostazol. The higher incidence of diarrhea, headache, and palpitations in the combination therapy group was comparable to previous reports and rarely resulted in treatment discontinuation [9,20,25]. No unexpected safety signals were identified, and no serious adverse events were considered related to study medication.…”

One-year follow-up of patients screened for lower extremity arterial disease

“…This positive change could be attributed to the increased walking distance achieved through medication therapies. According to our expectations, the greatest improvements were measured with patients taking cilostazol-containing medications, which is consistent with the results of other previous studies in the literature [26,[56][57][58][59].…”